Correlation analysis of interleukin-10 indicators and tumor necrosis factor-alpha as clinical indicators of rehabilitation treatment of postmastectomy lymphedema in patients after complex breast cancer treatment

Abstract

Background. Cellular immunity and cytotoxic agents are involved in the inflammatory process and tumor cell apoptosis resolution.Background. Cellular immunity and cytotoxic agents are involved in the inflammatory process and tumor cell apoptosis resolution. Endothelial cell apoptosis violation, imbalanced cytokines are considered as one of the contributory factors for postmastectomy lymphedema development.

Aim. To assess the correlation between the interleukin profile (interleukin-10 and tumor necrosis factor-alpha) and clinical indicators of postmastectomy lymphedema in the rehabilitation treatment course after complex breast cancer treatment

Materials and methods. The study involved 50 people aged 40–65 years. The main group consisted of 40 females who underwent a rehabilitation treatment course for postmastectomy lymphedema. The control group consisted of 10 females with a verified breast cancer diagnosis who were preparing for surgical treatment. The statistical analysis determined the differences between the mean values of indicators using the Mann-Whitney U-test and the Wilcoxon T-test. Spearman’s nonparametric correlation analysis was used to determine the relationship between the studied characteristics. Differences between indicators were considered statistically significant at p ≤ 0.05.

Results. The indices of the studied interleukins in the control group are significantly higher than that of the main group. Interleukin-10 remained unchanged in the course of restorative treatment, whereas tumor necrosis factor-alpha increased from 43.72 ± 10 pg/l to 118.94 ± 14.74 pg/l. After the course, a statistically significant correlation (p < 0.05) was found between the levels of the studied interleukins. A positive trend was observed as a result of rehabilitation treatment of postmastectomy lymphedema: the average excess volume in patients of the main group decreased by 38.5%.

Conclusion. Evaluation of interleukin-10 and tumor necrosis factor-alpha in patients with postmastectomy lymphedema allows not only the restorative treatment results assessment and determination of the immune status parameter and damage degree of the vascular endothelium of a particular patient but also prognosis formation of malignant neoplasm development.

Keywords

breast cancer / postmastectomy lymphedema / tumor necrosis factor-α / interleukin-10 / rehabilitation treatment

References

[1] Khetagurova AK, Miriusupova GF. Organization of rehabilitation of patients after mastectomy. Opyt prakticheskoj standartizacii. 2018;5(6):31-35. (In Russ).

[2] Хетагурова А.К., Мирюсупова Г.Ф. Организация реабилитации больных после мастэктомии // Опыт практической стандартизации. 2018. Т. 5, № 6. С. 31-35.

[3] Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-alpha) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol (Dordr). 2020;43(1):1-18. doi: 10.1007/s13402-019-00489-1c

[4] Cruceriu D., Baldasici O., Balacescu O., Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-alpha) in breast cancer: molecular insights and therapeutic approaches // Cell Oncol (Dordr). 2020. Vol. 43, N 1. P. 1-18. doi: 10.1007/s13402-019-00489-1

[5] Gantsev SK, Bakiyev RR. Local tissue interleukine profile in breast cancer. Russian Journal of Oncology. 2016;21(1-2):60-65. (In Russ). doi: 10.18821/1028-9984-2015-21-1-60-65

[6] Ганцев Ш.Х., Бакиев Р.Р. Локально-тканевый интерлейкиновый профиль при раке молочной железы // Российский онкологический журнал. 2016. Т. 21, № 1-2. С. 60-65. DOI: 10.18821/1028-9984-2015-21-1-60-65

[7] Korobeinikova E, Myrzaliyeva D, Ugenskiene R, et al. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients. BMC Genet. 2015;16:70. doi: 10.1186/s12863-015-0234-8

[8] Korobeinikova E., Myrzaliyeva D., Ugenskiene R., et al. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients // BMC Genet. 2015. Vol. 16, N. P. 70. doi: 10.1186/s12863-015-0234-8

[9] de Jesus Leite MAF, Puga GM, Arantes FJ, et al. Effects of combined and resistance training on the inflammatory profile in breast cancer survivors: A systematic review. Complement Ther Med. 2018;36:73-81. doi: 10.1016/j.ctim.2017.11.023

[10] de Jesus Leite M.A.F., Puga G.M., Arantes F.J., et al. Effects of combined and resistance training on the inflammatory profile in breast cancer survivors: A systematic review // Complement Ther Med. 2018. Vol. 36, N. P. 73-81. doi: 10.1016/j.ctim.2017.11.023

[11] Liu W, Lu X, Shi P, et al. TNF-alpha increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-kappaB pathway. Sci Rep. 2020;10(1):1804. doi: 10.1038/s41598-020-58642-y

[12] Liu W., Lu X., Shi P., et al. TNF-alpha increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-kappaB pathway // Sci Rep. 2020. Vol. 10, N 1. P. 1804. doi: 10.1038/s41598-020-58642-y

[13] Lv Z, Liu M, Shen J, et al. Association of serum interleukin-10, interleukin-17A and transforming growth factor-alpha levels with human benign and malignant breast diseases. Exp Ther Med. 2018;15(6):5475-5480. doi: 10.3892/etm.2018.6109

[14] Lv Z., Liu M., Shen J., et al. Association of serum interleukin-10, interleukin-17A and transforming growth factor-alpha levels with human benign and malignant breast diseases // Exp Ther Med. 2018. Vol. 15, N 6. P. 5475-5480. doi: 10.3892/etm.2018.6109

[15] Sheikhpour E, Noorbakhsh P, Foroughi E, et al. A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative. Rep Biochem Mol Biol. 2018;7(1):30-37. PMC6175593

[16] Sheikhpour E., Noorbakhsh P., Foroughi E., et al. A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative // Rep Biochem Mol Biol. 2018. Vol. 7, N 1. P. 30-37. PMC6175593

[17] Ma Y, Ren Y, Dai ZJ, et al. IL-6, IL-8 and TNF-alpha levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med. 2017;26(3):421-426. doi: 10.17219/acem/62120

[18] Ma Y., Ren Y., Dai Z.J., et al. IL-6, IL-8 and TNF-alpha levels correlate with disease stage in breast cancer patients // Adv Clin Exp Med. 2017. Vol. 26, N 3. P. 421-426. doi: 10.17219/acem/62120

[19] Kaur RP, Vasudeva K, Singla H, et al. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer. J Cell Physiol. 2018;233(12):9716-9723. doi: 10.1002/jcp.26901

[20] Kaur R.P., Vasudeva K., Singla H., et al. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer // J Cell Physiol. 2018. Vol. 233, N 12. P. 9716-9723. doi: 10.1002/jcp.26901

[21] Li Y, Gao P, Yang J, et al. Relationship between IL-10 expression and prognosis in patients with primary breast cancer. Tumour Biol. 2014;35(11):11533-11540. doi: 10.1007/s13277-014-2249-6

[22] Li Y., Gao P., Yang J., et al. Relationship between IL-10 expression and prognosis in patients with primary breast cancer // Tumour Biol. 2014. Vol. 35, N 11. P. 11533-11540. doi: 10.1007/s13277-014-2249-6

[23] Bhattacharjee HK, Bansal VK, Nepal B, et al. Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis? Indian J Surg Oncol. 2016;7(3):320-325. doi: 10.1007/s13193-016-0512-6

[24] Bhattacharjee H.K., Bansal V.K., Nepal B., et al. Is Interleukin 10 (IL10) Expression in Breast Cancer a Marker of Poor Prognosis? // Indian J Surg Oncol. 2016. Vol. 7, N 3. P. 320-325. doi: 10.1007/s13193-016-0512-6

[25] Saik OV, Nimaev VV, Usmonov DB, et al. Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem. BMC Med Genomics. 2019;12(Suppl 2):47. doi: 10.1186/s12920-019-0492-9

[26] Saik O.V., Nimaev V.V., Usmonov D.B., et al. Prioritization of genes involved in endothelial cell apoptosis by their implication in lymphedema using an analysis of associative gene networks with ANDSystem // BMC Med Genomics. 2019. Vol. 12, N Suppl 2. P. 47. doi: 10.1186/s12920-019-0492-9

[27] Siebert JC, Inokuma M, Waid DM, et al. An analytical workflow for investigating cytokine profiles. Cytometry A. 2008;73(4):289-298. doi: 10.1002/cyto.a.20509

[28] Siebert J.C., Inokuma M., Waid D.M., et al. An analytical workflow for investigating cytokine profiles // Cytometry A. 2008. Vol. 73, N 4. P. 289-298. doi: 10.1002/cyto.a.20509

[29] Liu D, Wang X, Chen Z. Tumor Necrosis Factor-alpha, a Regulator and Therapeutic Agent on Breast Cancer. Curr Pharm Biotechnol. 2016;17(6):486-494. doi: 10.2174/1389201017666160301102713

[30] Liu D., Wang X., Chen Z. Tumor Necrosis Factor-alpha, a Regulator and Therapeutic Agent on Breast Cancer // Curr Pharm Biotechnol. 2016. Vol. 17, N 6. P. 486-494. doi: 10.2174/1389201017666160301102713

[31] Ermoshchenkova MV, Filonenko EV, Zikiryakhodzhaev AD. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu postmastektomicheskogo sindroma. Moscow; 2013. (In Russ).

[32] Ермощенкова М.В., Филоненко Е.В., Зикиряходжаев А.Д. Федеральные клинические рекомендации по диагностике и лечению постмастэктомического синдрома. Москва, 2013.

[33] Agranovich NV, Sivolapova MS, Koychuev AA, Agranovich OV. Change of immune status parameters, clinical symptoms and health related quality of life patients with postmastectomy syndrome depending on the used rehabilitation complexes. Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul’tury. 2020;97(6):17. (In Russ). doi: 10.17116/kurort20209706117

[34] Агранович Н.В., Сиволапова М.С., Койчуев А.А., Агранович О.В. Изменение показателей иммунного статуса, клинических симптомов и качества жизни пациенток с постмастэктомическим синдромом в зависимости от применяемых комплексов реабилитации // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2020. Т. 97, № 6. С. 17-26. doi: 10.17116/kurort20209706117

[35] Silkov AN, Cherdyntseva NV, Maximov VN, Sennikov SV. Promoter Polymorphisms of Genes Encoding Tumor Necrosis Factor and Interleukin-1 in Breast Cancer Patients. Medical Immunology (Russia). 2017;19(2):185-190. (In Russ). doi: 10.15789/1563-0625-2017-2-185-190

[36] Силков А.Н., Чердынцева Н.В., Максимов В.Н., Сенников С.В. Полиморфизм промоторов генов рецепторов фактора некроза опухоли и интерлейкина-1 у больных раком молочной железы // Медицинская иммунология. 2017. Т. 2, № 2. С. 185-190. doi: 10.15789/1563-0625-2017-2-185-190

[37] Agranovich NV, Sivolapova MS. Opportunities and substantiation of application methods of physical therapy in rehabilitation of patients with oncopathology of mammary gland. Resort medicine.2018;(2):59-64.

[38] Агранович Н.В., Сиволапова М.С. Возможности и обоснование применения методов физиотерапии в реабилитации больных с онкопатологией молочной железы // Курортная медицина. 2018. № 2. С. 59-64.

[39] Grushina TI. What physiotherapeutic method for the treatment of post-mastectomy lymphedema is the most effective? Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kul’tury. 2017;94(4):59. (In Russ). doi: 10.17116/kurort201794459-66

[40] Грушина Т.И. Какой метод физиотерапии постмастэктомической лимфедемы наиболее эффективен? // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2017. Т. 94, № 4. С. 59-66. doi: 10.17116/kurort201794459-66

[41] Patent RUS №2737357/ 2011.08.03. Agranovich NV, Sivolapova MS, Koichuev AA, Agranovich OV. Sposob vosstanovitel’nogo lecheniya oslozhnenii posle operatsii na molochnoi zheleze. Available from: https://yandex.ru/patents/doc/RU2487741C2_20130720. (In Russ).

[42] Патент РФ на изобретение № 2737357/ 2011.08.03. Агранович Н.В., Сиволапова М.С., Койчуев А.А., Агранович О.В. Способ восстановительного лечения осложнений после операции на молочной железе. Режим доступа: https://yandex.ru/patents/doc/RU2487741C2_20130720. Дата обращения: 01.10.2021

[43] Tishakova VE, Filonenko EV, Chissov VI, et al. Physical Methods of Rehabilitation in Cancer Patients after Combined Modality Treatment for Breast Cancer. Biomedical Photonics. 2017;6(1):28-37. (In Russ). doi: 10.24931/2413-9432-2017-6-1-28-37

[44] Тишакова В.Э., Филоненко Е.В., Чиссов В.И., и др. Физические методы реабилитации онкологических больных после комбинированного лечения рака молочной железы // Biomedical Photonics. 2017. Т. 6, № 1. С. 28-37. doi: 10.24931/2413-9432-2017-6-1-28-37

[45] Sidorov D.B., Grushina T.I. The effectiveness of the use of preformed physical factors and subcutaneous surgical correction in the rehabilitation of patients with breast cancer with late lymphedema of the upper limb. Bulletin of rehabilitation medicine. 2019;(6):39-44. (In Russ).

[46] Сидоров Д.Б., Грушина Т.И. Эффективность применения преформированных физических факторов и подкожной хирургической коррекции в реабилитации больных раком молочной железы с поздней лимфедемой верхней конечности // Вестник восстановительной медицины. 2019. № 6. С. 39-44.

[47] Galasheva Z, Poskotinova L. The Role of Interleukin-6 and Interleukin-10 in the Nervous System Function at the Early and Mature Stages of Ontogeny. Vestnik of Northern (Arctic) Federal University named after MVLomonosov Series “Medical and Biological Sciences”. 2016(3):5-17. (In Russ). doi: 10.17238/issn2308-3174.2016.3.5

[48] Галашева З.В., Поскотинова Л.В. Роль интерлейкина-6 и интерлейкина-10 в функционировании нервной системы на раннем и зрелом этапах онтогенеза // Журнал медико-биологических исследований. 2016. № 3. С. 5–17. doi: 10.17238/issn2308-3174.2016.3.5

RIGHTS & PERMISSIONS

Eco-Vector